Galectin-1 is a small sugar-binding protein that acts as a molecular multitasker across the body, dampening inflammation, helping tumors hide from the immune system, and guiding tissue repair after injury. It belongs to the galectin family of lectins, proteins that recognize and bind specific sugar chains on cell surfaces, and its influence reaches into nearly every branch of biomedicine. What makes galectin-1 unusual is that the same protein can serve profoundly different roles depending on context: in one setting it calms a destructive autoimmune attack, and in another it shields a growing tumor from the very immune cells that should destroy it.
How Galectin-1 Recognizes Its Targets
Galectin-1 works by latching onto sugar structures called beta-galactosides, which are chains of sugar molecules displayed on the surfaces of cells and in the spaces between them. The protein forms a dimer, meaning two identical copies pair up, each carrying a carbohydrate recognition domain that can grab onto these sugars. When one of these binding sites locks onto a sugar, the protein undergoes a structural shift: the loops around the binding pocket tighten, while other parts of the molecule become more flexible. Interestingly, binding at the first site actually makes the second site weaker, a phenomenon called negative cooperativity, so the two halves do not grab their targets with equal strength.1PubMed. Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity
On real cells, the main targets for galectin-1 are complex sugar chains attached to proteins, particularly the branched structures found on many cell-surface receptors.2Glycobiology. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells The specifics matter because they determine which cells galectin-1 “sees.” In some tissues, terminal alpha-linked galactose residues on sugar chains serve as the preferred binding partner, rather than the more commonly assumed N-acetyllactosamine.3PubMed. Terminal alpha-linked galactose rather than N-acetyl lactosamine is ligand for bovine heart galectin-1 in N-linked oligosaccharides of glycoproteins This variability in sugar preference is part of what gives galectin-1 such diverse biological roles: different cell types display different sugar coats, and galectin-1 reads those coats to decide what to do.
Taming the Immune System
One of galectin-1’s best-studied functions is its ability to kill activated T cells. When T cells become activated during an immune response, their surface sugar patterns change, making them visible to galectin-1. The protein then triggers apoptosis, a controlled form of cell death, in those activated T cells. Resting T cells bind galectin-1 too, but they do not die, meaning the protein selectively culls the active immune responders while leaving the dormant ones alone. This process depends on the surface molecule CD45 and on the type of sugar chains the T cell carries.4PubMed. Apoptosis of T cells mediated by galectin-1 The discovery that an endogenous mammalian lectin could trigger immune cell death opened up an entirely new way of thinking about how the body regulates its own defenses.
Beyond killing T cells outright, galectin-1 also reshapes the immune landscape in subtler ways. It promotes the development of tolerogenic dendritic cells, which are immune sentinels that teach the system to stand down rather than attack. These tolerogenic cells, in turn, encourage the generation of regulatory T cells that actively suppress inflammatory responses. In mouse models of autoimmune brain inflammation, galectin-1 proved essential for establishing immune tolerance when antigens were delivered intravenously, a finding with implications for autoimmune therapies.5PubMed Central. Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis
Galectin-1 also shifts macrophages, another key immune cell type, toward an anti-inflammatory profile. When galectin-1 was incorporated into scaffold materials used in tissue engineering, macrophages exposed to it produced more arginase-1 (a marker of the anti-inflammatory, repair-oriented state) and less of the inflammatory molecules iNOS and IL-6.6PubMed Central. Galectin-1 Promotes an M2 Macrophage Response to Polydioxanone Scaffolds This capacity to calm macrophages is part of what makes galectin-1 relevant for wound healing and tissue engineering, topics covered later in this article.
Galectin-1 in Autoimmune Disease
The anti-inflammatory properties of galectin-1 become especially meaningful in the context of autoimmune diseases, where the immune system attacks the body’s own tissues. In experimental arthritis, mice genetically engineered to lack galectin-1 developed more severe joint disease than normal mice, suggesting that the body’s natural galectin-1 acts as a built-in brake on the arthritis process.7The Journal of Immunology. Endogenous Galectin-1 Exerts Tonic Inhibition on Experimental Arthritis When researchers went a step further and delivered galectin-1 directly into arthritic rat joints using gene therapy, the treated animals showed reduced joint damage, lower inflammation scores, and fewer invading immune cells.8PubMed. Intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis
Similar protective effects have been observed in the eye. In models of acute ocular inflammation, galectin-1 treatment reduced the infiltration of inflammatory cells, decreased levels of pro-inflammatory molecules like IL-1β and IL-6, and improved the overall tissue damage picture.9PubMed Central. Protective effects of the galectin-1 protein on in vivo and in vitro models of ocular inflammation And in kidney injury caused by restricted blood flow, galectin-1 treatment protected organ function, reduced oxidative stress, and lowered the number of inflammatory cells entering the damaged tissue, performing comparably to or better than the standard anti-inflammatory drug dexamethasone.10Scientific Reports. Pharmacological treatment with galectin-1 protects against renal ischaemia-reperfusion injury
How Tumors Exploit Galectin-1
If galectin-1’s immune-calming properties sound beneficial, they have a dark side in cancer. Tumors face the constant threat of being destroyed by T cells, and many cancers have found a way to weaponize galectin-1 to create an immune-suppressive microenvironment. In head and neck cancers, for instance, tumor-secreted galectin-1 prevents T cells from migrating into the tumor itself. It does this in part by reprogramming the blood vessels within the tumor to display immune checkpoint molecules, including PD-L1 and galectin-9, on their surfaces, effectively posting “keep out” signs that discourage T cell entry.11JCI Insight. Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance This T cell exclusion may also contribute to resistance against checkpoint immunotherapies, since even drugs that release the immune system’s brakes cannot help if T cells never reach the tumor in the first place.
Galectin-1 also directly promotes the growth of new blood vessels that feed tumors, a process called angiogenesis. It does this by binding to sugar structures on VEGF receptor 2, a key receptor on endothelial cells that line blood vessels. Once bound, galectin-1 activates the receptor and triggers growth-promoting signals in a way that mimics the normal angiogenic factor VEGF-A but is completely independent of it.12Cell. Remodeling of the Endothelial Glycome Defines Galectin-1-Driven Angiogenesis and Anti-VEGF Resistance This is clinically significant because it means that tumors with high galectin-1 levels can continue building their blood supply even when treated with anti-VEGF drugs like bevacizumab, a common reason for anti-angiogenic therapy failure.13Cancer Discovery. Galectin-1 Maintains Angiogenesis in Anti-VEGF–Refractory Tumors
Driving Cancer Spread
Beyond shielding tumors from immune attack and feeding them with new blood vessels, galectin-1 actively promotes metastasis. It does so by driving a process called the epithelial-mesenchymal transition (EMT), where cancer cells shed their anchored, tissue-like identity and take on a mobile, invasive phenotype capable of traveling to distant organs. This has been documented in multiple cancer types, each involving somewhat different signaling pathways. In gastric cancer, galectin-1 activates the hedgehog signaling pathway through an unconventional route to drive invasion.14PubMed Central. Galectin-1 induces invasion and the epithelial-mesenchymal transition in human gastric cancer cells via non-canonical activation of the hedgehog signaling pathway In ovarian cancer, galectin-1 enhances migration and invasion through the JNK/p38 signaling pathway.15PubMed Central. Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway In pancreatic cancer, cells from the supportive tissue surrounding the tumor secrete galectin-1, which then pushes cancer cells toward EMT through yet another route, the NF-κB pathway.16PubMed Central. PSC-derived Galectin-1 inducing epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma cells by activating the NF-κB pathway
The fact that galectin-1 can trigger EMT through multiple distinct signaling cascades across different cancers suggests it sits at a regulatory node that is not specific to one tumor type. Compounding the problem, hypoxia, the low-oxygen environment common in fast-growing tumors, drives galectin-1 production upward. The master hypoxia-response protein HIF-1α directly increases galectin-1 expression, creating a vicious cycle: oxygen-starved tumors make more galectin-1, which builds more blood vessels and promotes more invasive behavior.17Carcinogenesis. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells
Unsurprisingly, higher galectin-1 levels in tumor tissue correlate with worse patient outcomes. A meta-analysis pooling data across cancer types found that high galectin-1 expression was associated with roughly 80% higher mortality risk, with digestive cancers showing a particularly strong association.18PubMed Central. Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis A second pooled analysis reported an even more pronounced association and found the link held across multiple outcome measures including disease-free survival and progression-free survival.19PubMed Central. Pooling analysis reveals that galectin-1 is a reliable prognostic biomarker in various cancers Breast cancer patients with higher galectin-1 have also been found to show increased populations of tolerogenic dendritic cells in their blood, one concrete mechanism linking elevated galectin-1 to weakened anti-tumor immunity.20PubMed. Myosin IIa activation is crucial in breast cancer derived galectin-1 mediated tolerogenic dendritic cell differentiation
Nerve Repair After Injury
Galectin-1’s roles extend well beyond the immune system and cancer. It plays a striking part in regeneration, particularly in nerves. When a peripheral nerve is cut or crushed, the damaged area releases galectin-1 from Schwann cells (the support cells that insulate nerve fibers) and from the injured axons themselves. In the extracellular space, galectin-1 becomes oxidized, and this oxidized form stimulates macrophages to secrete factors that promote axonal regrowth and Schwann cell migration toward the injury site.21Journal of Neuroscience. Oxidized Galectin-1 Stimulates Macrophages to Promote Axonal Regeneration in Peripheral Nerves after Axotomy
Recombinant human galectin-1 can enhance this process when supplied externally. In both test-tube nerve models and live rat experiments with severed peripheral nerves, tiny amounts of the protein boosted axonal regrowth. Conversely, blocking galectin-1 with antibodies strongly inhibited regeneration in vivo.22PubMed Central. Galectin-1 regulates initial axonal growth in peripheral nerves after axotomy The amounts needed are remarkably small, active at concentrations two orders of magnitude lower than those required for its sugar-binding activity, hinting that nerve regeneration relies on a mechanism distinct from its classical lectin function.
Even more ambitious work has explored galectin-1 in spinal cord injury, a far more challenging repair scenario. In its dimeric form, galectin-1 promoted reactivation of the internal scaffolding that allows nerve fibers to grow, and in animal models of acute and chronic spinal cord injury this translated into axonal regrowth, re-formation of synapses, remyelination, and recovery of coordinated movement.23Experimental Neurology. Ligand-mediated Galectin-1 endocytosis prevents intraneural H2O2 production promoting F-actin dynamics reactivation and axonal re-growth These are preclinical results, not human trials, but they point to galectin-1 as one of the more promising molecules in the notoriously difficult field of nerve regeneration research.
Muscle Regeneration and Wound Healing
Galectin-1 is also involved in how skeletal muscle rebuilds itself after injury. Normally, after muscle damage, satellite cells (muscle stem cells) activate, multiply, and fuse together to form new muscle fibers. Galectin-1 levels rise in activated satellite cells after injury, and when its function is blocked with antibodies, the resulting muscle fibers are smaller and less mature.24PubMed. Galectin-1 is a novel factor that regulates myotube growth in regenerating skeletal muscles Mice that completely lack galectin-1 show impaired muscle cell fusion and delayed muscle development.25Developmental Dynamics. Lack of galectin‐1 results in defects in myoblast fusion and muscle regeneration
In a particularly striking set of experiments, human fetal mesenchymal stem cells exposed to galectin-1 converted into muscle cells at high rates, with about two-thirds adopting a muscle identity and forming long, multinucleated fibers. When these galectin-1-treated cells were transplanted into mice with muscular dystrophy, they generated four times more human muscle fibers than untreated cells.26PubMed. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration This finding has been discussed as relevant to future cell-based therapies for muscular dystrophies, though such therapies remain experimental.
Skin wound healing benefits from galectin-1 as well. The protein activates myofibroblasts, the cells responsible for contracting and closing wounds, and promotes their migration and proliferation.27PubMed. Galectin-1 accelerates wound healing by regulating the neuropilin-1/Smad3/NOX4 pathway and ROS production in myofibroblasts In rat wound models, galectin-1 had a measurable positive effect on skin wound closure.28Cells Tissues Organs. Human Galectins Induce Conversion of Dermal Fibroblasts into Myofibroblasts and Production of Extracellular Matrix: Potential Application in Tissue Engineering and Wound Repair However, there is a catch: when galectin-1 is persistently overproduced at a wound site, it drives excess production of extracellular matrix and enhanced blood vessel growth through the PI3K/Akt pathway, which can lead to keloid formation, the raised, overgrown scars that extend beyond the original wound.29PubMed Central. Galectin 1-A Key Player between Tissue Repair and Fibrosis Galectin-1’s wound healing role is therefore dose- and duration-dependent: enough helps, but too much for too long tips the balance from repair into pathological scarring.
The Cardiovascular Connection
Research over the past decade has established that galectin-1 plays a role in cardiovascular health, and once again the story is one of dual potential. In atherosclerosis, galectin-1 appears to be protective. Mice lacking the protein developed more severe plaque buildup, and their vascular smooth muscle cells shifted away from a stable, contractile state toward a disease-promoting phenotype. Treatment with recombinant galectin-1 reversed these effects and also reduced the severity of aortic aneurysms in the same experimental models. Human artery samples from patients with atherosclerosis or aortic aneurysm showed lower galectin-1 expression compared to healthy tissue, suggesting the protein’s decline may contribute to disease progression.30PubMed Central. Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
But just as in cancer, context determines outcome. In patients undergoing coronary angiography, those with the highest circulating galectin-1 levels had a dramatically higher risk of major adverse cardiovascular events, even after adjusting for a wide range of other risk factors.31Scientific Reports. Galectin-1 is associated with the severity of coronary artery disease and adverse cardiovascular events in patients undergoing coronary angiography A recent review synthesizing a decade of cardiovascular research concluded that while galectin-1 supports endothelial integrity and immune modulation, its dysregulation can contribute to disease progression through pro-inflammatory signaling, fibrosis, and harmful cardiac remodeling.32PubMed Central. Galectin-1 in Cardiovascular Pathogenesis: Unraveling Dual Roles and Mechanistic Insights in Emerging Research The apparent contradiction, protective in some cardiovascular settings and a danger sign in others, likely reflects the difference between galectin-1 doing its homeostatic job in healthy vessels and being elevated as part of an ongoing disease process.
The Redox Switch
One reason galectin-1 can have such different effects in different settings is that it is exquisitely sensitive to the chemical environment around it, particularly to oxidation. The protein contains several cysteine residues that are vulnerable to oxidative damage. When galectin-1 becomes oxidized, it loses its sugar-binding ability, which fundamentally changes what it can do. Reduced (non-oxidized) galectin-1 is the form that binds sugars and triggers effects like T cell death, while oxidized galectin-1 takes on distinct roles, like stimulating macrophages during nerve repair as described earlier.
The monomer-dimer balance also plays into this. When two galectin-1 molecules are paired as a dimer, the protein is more resistant to oxidation. Binding to sugars promotes dimerization, creating a kind of feedback loop: when galectin-1 finds its targets, it stabilizes itself against being inactivated by the oxidative environment.33PubMed Central. Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimer formation A mutant form of galectin-1 that cannot dimerize properly still recognizes sugars but is rapidly inactivated by oxidation, confirming that dimerization is a protective mechanism. When the protein was artificially stabilized against oxidation, it could sustain its biological signals indefinitely.
Recent work has refined this picture, showing that under mild oxidizing conditions, galectin-1 breaks into at least three structurally distinct monomeric forms, while the reduced version produces only one. At low concentrations, reduced and oxidized galectin-1 bind sugars similarly, but at higher concentrations the reduced form binds about ten times more strongly.34PubMed. Impact of galectin-1’s redox state on its lectin activity and monomer-dimer equilibrium. Focusing on oxidized Gal-1 This concentration-dependent behavior may help explain why galectin-1’s effects vary so much between tissues and disease states: the local oxygen level, the availability of binding partners, and the protein’s concentration all interact to determine which form predominates and what it does.
Therapeutic Prospects and Obstacles
Given galectin-1’s pro-tumor activities, blocking it in cancer is an obvious therapeutic goal. The most advanced small-molecule inhibitor studied so far is OTX008, which selectively targets galectin-1 and has shown promising results in preclinical models. In ovarian cancer xenografts, OTX008 inhibited tumor growth and reduced both the density of blood vessels within tumors and the expression of VEGF receptor 2.35PubMed. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis In head and neck cancer models, OTX008 reduced tumor growth by roughly a quarter on average, comparable to the anti-VEGF antibody bevacizumab (Avastin) in the same model.36PubMed Central. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models
The central challenge of galectin-1 therapeutics, however, is the protein’s dual nature. Blocking it in a tumor makes immunological sense, but systemic blockade could undermine the very anti-inflammatory functions that protect against autoimmune disease, impair nerve and muscle regeneration, and potentially worsen cardiovascular remodeling. Any drug targeting galectin-1 in cancer would ideally need to be either highly localized to the tumor or delivered in a way that spares its beneficial activity elsewhere in the body. This tension between wanting to block galectin-1 in some tissues and preserve it in others is one of the defining challenges for the field going forward.
Galectin-1 and Infectious Disease
The galectin family’s sugar-binding ability extends to the surfaces of pathogens as well. Galectins, including galectin-1, can recognize sugar chains on the surfaces of bacteria, viruses, fungi, and parasites, functioning as part of the body’s innate immune defense. In some cases, galectin-1 binding to a pathogen flags it for immune destruction. But certain parasites have evolved to turn this recognition system against the host, co-opting galectin-1 to facilitate their own attachment to or invasion of host cells.37PubMed Central. Roles of galectins in infection This is a less-studied dimension of galectin-1 biology, but it reinforces a theme: the protein’s effects depend heavily on what is wearing the sugars it recognizes. A sugar chain on a parasite and a sugar chain on a T cell look similar to galectin-1, but the downstream consequences of binding are radically different.
An Ancient and Conserved Protein
Galectin-1 is not a recent evolutionary invention. Phylogenetic analysis of the galectin family across vertebrates indicates that all galectin carbohydrate recognition domains trace back to a single ancestral domain. The more complex family members with two recognition domains arose through gene duplication early in vertebrate evolution, and the overall family has been conserved ever since.38Molecular Biology and Evolution. Phylogenetic Analysis of the Vertebrate Galectin Family The fact that galectin-1 has been retained over hundreds of millions of years of evolution underscores its fundamental importance. Organisms that lost or drastically altered this protein presumably faced significant survival disadvantages, whether from uncontrolled immune responses, poor wound healing, or compromised nerve repair. The evolutionary depth also helps explain why galectin-1 is entangled in so many biological processes: a protein present in every vertebrate lineage has had a long time to be co-opted for new roles.